Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 18/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6522804 | 0.99 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3CYP2D6CHRNB2 | |
| SCHEMBL2398995 | 0.83 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| Fumaric Acid SCHEMBL1936048 | 0.78 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL2398246 | 0.74 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL1936050 | 0.74 | SLC6A4 (0.37) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL2397591 | 0.74 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL15955652 | 0.70 | ALDH1A1 (0.52) | — | |
| SCHEMBL6521921 | 0.69 | HTR2C (0.43) | SLC6A4SLC6A2KCNH2 | |
| SCHEMBL2396105 | 0.69 | ALDH1A1 (0.35) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2398798 | 0.69 | SLC6A2 (0.43) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053985-A1 | NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-03-03 | — | — | US | claimed |
| EP-2245011-A1 | NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2010-11-03 | — | — | EP | claimed |
| WO-2009090173-A1 | NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-07-23 | — | — | WO | claimed |
| US-20110053985-A1 | NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-03-03 | — | — | US | disclosed |
| EP-2245011-A1 | NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009090173-A1 | NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053985-A1 | NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | SLC6A4 4/4885SLC6A2 2/4885SLC6A3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.